EMD Serono Acquires PostEra's Two Fertility Drug Programs
EMD Serono, the US/Canada healthcare business of Merck KGaA, acquired two of PostEra's AI-discovered small molecule fertility programs targeting FSHR and LHCGR.
Read the full coverage, free
- Read at PR NewswireFree
- Also at PR Newswire →
- Also at PR Newswire →
- Also at PR Newswire →
- Also at PR Newswire →
We only link to sources you can read without a subscription. How we check.